Lyra Therapeutics reported revenue of $0.01M and net income of -$6.95M for the quarter ended Dec 2025, down 96.7% year over year. This income statement covers 28 quarters of results from Mar 2019 through Dec 2025, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Mar2019 | Jun2019 | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 0.26M | 0.26M | 0.26M | 0.26M | 0.26M | 0.64M | 0.64M | 0.64M | 0.64M | 0.99M | 0.99M | 1.14M | 1.22M | 1.31M | 1.31M | 1.31M | 1.32M | 1.35M | 1.64M | 1.77M | ||||||||
| Revenue & cost | ||||||||||||||||||||||||||||
| Revenue | 0.01M | 0.27M | 0.47M | 0.53M | 0.36M | 0.01M | 0.41M | 0.46M | 0.54M | 0.15M | 0.53M | 0.60M | 0.20M | 0.21M | 0.18M | 0.18M | 0.03M | 0.01M | ||||||||||
| Operating items | ||||||||||||||||||||||||||||
| Research & DevelopmentR&D | 4.77M | 7.50M | 7.08M | 10.34M | 8.51M | 10.79M | 10.05M | 9.45M | 12.60M | 10.80M | 12.37M | 12.27M | 18.24M | 13.26M | 5.90M | 6.36M | 4.88M | 5.11M | 4.05M | 4.38M | ||||||||
| Selling, General & AdministrativeSG&A | 3.06M | 3.56M | 4.02M | 3.57M | 3.89M | 4.13M | 5.14M | 4.40M | 5.13M | 4.57M | 5.00M | 4.36M | 5.82M | 5.14M | 3.93M | 3.61M | 3.26M | 3.50M | 2.24M | 2.54M | ||||||||
| Restructuring CostsRestructuring | 6.45M | 2.80M | 1.65M | 0.90M | 0.40M | -0.02M | 0.20M | |||||||||||||||||||||
| Other Operating ExpensesOther Opex | 1.32M | 1.59M | 24.72M | -0.00M | -0.01M | -0.00M | 0.01M | |||||||||||||||||||||
| Operating ExpensesOpex | 7.83M | 11.06M | 11.10M | 13.91M | 12.39M | 14.93M | 15.19M | 15.17M | 17.72M | 16.96M | 17.37M | 16.62M | 24.06M | 49.57M | 12.64M | 11.62M | 9.02M | 9.01M | 6.26M | 7.12M | ||||||||
| Operating IncomeOp. Inc | -7.83M | -11.06M | -11.08M | -13.64M | -11.93M | -14.40M | -14.83M | -15.15M | -17.31M | -16.50M | -16.83M | -16.48M | -23.52M | -48.97M | -12.44M | -11.41M | -8.84M | -8.83M | -6.24M | -7.12M | ||||||||
| EBIT | -7.83M | -11.06M | -11.08M | -13.64M | -11.93M | -14.40M | -14.83M | -15.15M | -17.31M | -16.50M | -16.83M | -16.48M | -23.52M | -48.97M | -12.44M | -11.41M | -8.84M | -8.83M | -6.24M | -7.12M | ||||||||
| Non-operating items | ||||||||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.03M | 0.03M | 0.03M | 0.02M | 0.01M | 0.03M | 0.06M | 0.93M | 1.07M | 0.90M | 1.19M | 1.34M | 1.09M | 0.85M | 0.58M | 0.43M | 0.30M | 0.41M | 0.26M | 0.17M | ||||||||
| Non Operating IncomeNon Op. Inc. | 0.03M | 0.03M | 0.03M | 0.02M | 0.01M | 0.03M | 0.06M | 0.93M | 1.07M | 0.90M | 1.19M | 1.34M | 1.09M | 0.85M | 0.58M | 0.43M | 0.30M | 1.39M | 0.26M | 0.17M | ||||||||
| Net income details | ||||||||||||||||||||||||||||
| EBT | -7.80M | -11.04M | -11.05M | -13.62M | -11.91M | -14.37M | -14.77M | -14.22M | -16.24M | -15.61M | -15.63M | -15.14M | -22.44M | -48.12M | -11.87M | -10.97M | -8.54M | -7.43M | -5.98M | -6.95M | ||||||||
| Tax ProvisionsTaxes | 0.01M | 0.01M | 0.02M | 0.02M | 0.01M | 0.01M | 0.01M | -19.65M | 0.00M | 0.00M | 0.00M | -6.08M | ||||||||||||||||
| Profit After TaxPAT | -7.80M | -11.04M | -11.05M | -13.61M | -11.91M | -14.37M | -14.77M | -14.26M | -16.25M | -15.62M | -15.65M | -15.16M | -22.45M | -48.13M | -11.87M | -11.00M | -8.55M | -7.44M | -5.98M | -6.95M | ||||||||
| Income from Continuing OperationsIncome (Continuing) | -7.80M | -11.04M | -11.05M | -13.62M | -11.91M | -14.37M | -14.77M | -14.22M | -16.25M | -15.62M | -15.65M | -15.16M | -22.45M | -48.13M | -11.87M | 8.67M | -8.55M | -7.44M | -5.98M | -0.87M | ||||||||
| Consolidated Net IncomeConsol Net Inc. | -7.80M | -11.04M | -11.05M | -13.62M | -11.91M | -14.37M | -14.77M | -14.22M | -16.25M | -15.62M | -15.65M | -15.16M | -22.45M | -48.13M | -11.87M | 8.67M | -8.55M | -7.44M | -5.98M | -0.87M | ||||||||
| Income towards Parent CompanyParent Net Inc | -7.80M | -11.04M | -11.05M | -13.62M | -11.91M | -14.37M | -14.77M | -14.22M | -16.25M | -15.62M | -15.65M | -15.16M | -22.45M | -48.13M | -11.87M | 8.67M | -8.55M | -7.44M | -5.98M | -0.87M | ||||||||
| Net Income towards Common StockholdersNet Income | -7.80M | -11.04M | -11.05M | -13.62M | -11.91M | -14.37M | -14.77M | -14.22M | -16.25M | -15.62M | -15.65M | -15.16M | -22.45M | -48.13M | -11.87M | 8.67M | -8.55M | -7.44M | -5.98M | -0.87M | ||||||||
| Additional items | ||||||||||||||||||||||||||||
| EPS (Basic) | -30.13 | -42.48 | -42.51 | -52.43 | -45.78 | -21.16 | -20.05 | -23.52 | -22.07 | -17.88 | -13.74 | -15.22 | -17.54 | -36.76 | -9.07 | 6.66 | -6.50 | -5.51 | -3.38 | -0.56 | ||||||||
| EPS (Diluted) | -30.13 | -42.48 | -42.51 | -52.43 | -45.78 | -21.16 | -20.05 | -23.52 | -22.07 | -17.88 | -13.74 | -15.22 | -17.54 | -36.76 | -9.07 | 6.66 | -6.50 | -5.51 | -3.38 | -0.56 | ||||||||
| Shares Outstanding | 0.26M | 0.26M | 0.26M | 0.26M | 0.26M | 0.68M | 0.74M | 0.60M | 0.74M | 0.87M | 1.14M | 1.00M | 1.28M | 1.31M | 1.31M | 1.30M | 1.32M | 1.35M | 1.77M | 1.55M | ||||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 0.26M | 0.26M | 0.26M | 0.26M | 0.26M | 0.68M | 0.74M | 0.60M | 0.74M | 0.87M | 1.14M | 1.00M | 1.28M | 1.31M | 1.31M | 1.30M | 1.32M | 1.35M | 1.77M | 1.55M | ||||||||
| EBITDA | -7.83M | -11.06M | -11.08M | -13.64M | -11.93M | -14.40M | -14.83M | -15.15M | -17.31M | -16.50M | -16.83M | -16.48M | -23.52M | -48.97M | -12.44M | -11.41M | -8.84M | -8.83M | -6.24M | -7.12M | ||||||||
| Tax Rate | -0.09 | -0.08 | -0.10 | -0.11 | -0.06 | -0.02 | -0.06 | 179.05 | -0.05 | -0.03 | -0.05 | 87.48 |